Clinical application of tadalafil in dogs with pulmonary hypertension: a retrospective study
Open Access
- 28 February 2026
- journal article
- Published by The Korean Society of Veterinary Science (KJVR) in Korean Journal of Veterinary Research
- Vol. 66 (1) , e2
Abstract
Pulmonary hypertension (PH) is characterized by abnormally increased pressure within the pulmonary vasculature. Phosphodiesterase type 5 (PDE5) inhibitors are commonly used to manage PH, and tadalafil, a PDE5 inhibitor with a longer half-life than sildenafil, has rarely been investigated in veterinary medicine. This retrospective study analyzed medical records of dogs treated with tadalafil at the Veterinary Medical Teaching Hospital of Jeju National University between January 2021 and July 2023. Eleven dogs tentatively diagnosed with PH received tadalafil at an initial dosage of 1 mg/kg once daily and were monitored for over 4 weeks. Efficacy and adverse effects were evaluated based on history and physical examination findings. Ten dogs had previously received sildenafil, while one dog was treated with tadalafil as first‐line therapy. Nausea occurred in one case. Seven of 11 dogs achieved at least partial remission, whereas 4 showed no improvement. Notably, 8 dogs (72.7%) were receiving concomitant medications targeting the underlying diseases causing PH, which may have contributed to symptom improvement and influenced clinical outcomes. Thus, although tadalafil at 1 mg/kg once daily was generally well tolerated and appeared to provide acceptable control of PH, its efficacy should be interpreted cautiously given the small sample size. It may be particularly beneficial when the underlying diseases causing PH are adequately managed with concomitant therapies, within the context of multimodal treatment.Keywords
This publication has 19 references indexed in Scilit:
- Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot studyJournal of Veterinary Cardiology, 2019
- Phosphodiesterase 5 inhibitors for pulmonary hypertensionCochrane Database of Systematic Reviews, 2019
- Safety and Long-Term Efficacy of Transition from Sildenafil to Tadalafil due to Side Effects in Patients with Pulmonary Arterial HypertensionLung, 2014
- Comparison of the Therapeutic and Side Effects of Tadalafil and Sildenafil in Children and Adolescents with Pulmonary Arterial HypertensionPediatric Cardiology, 2013
- Safety, Tolerability, and Efficacy of Overnight Switching From Sildenafil to Tadalafil in Patients With Pulmonary Arterial HypertensionCardiovascular Therapeutics, 2013
- Transition of PH Patients from Sildenafil to Tadalafil: Feasibility and Practical ConsiderationsLung, 2012
- Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: A case series of 12 patientsInternational Journal of Cardiology, 2008
- Sildenafil Citrate Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2005
- Clinical efficacy of sildenafil in primary pulmonary hypertension. A randomized, placebo-controlled, double-blind, crossover studyACC Current Journal Review, 2004
- Mechanisms of action of PDE5 inhibition in erectile dysfunctionInternational Journal Of Impotence Research, 2004